BioAge Financial Statements From 2010 to 2024

BIOA Stock   19.14  0.70  3.80%   
BioAge Labs, financial statements provide useful quarterly and yearly information to potential BioAge Labs, investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BioAge Labs, financial statements helps investors assess BioAge Labs,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BioAge Labs,'s valuation are summarized below:
Market Capitalization
674.1 M
Earnings Share
(5.40)
We have found one hundred twenty available fundamental signals for BioAge Labs,, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BioAge Labs, prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. As of November 23, 2024, Market Cap is expected to decline to about 383 M. In addition to that, Enterprise Value is expected to decline to about 388.5 M

BioAge Labs, Total Revenue

0.0

Check BioAge Labs, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAge Labs,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 153.9 K, Interest Expense of 5.7 M or Selling General Administrative of 9.2 M, as well as many indicators such as Price To Sales Ratio of 56.15, Ptb Ratio of 33.21 or Days Sales Outstanding of 119. BioAge financial statements analysis is a perfect complement when working with BioAge Labs, Valuation or Volatility modules.
  
Check out the analysis of BioAge Labs, Correlation against competitors.
For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.

BioAge Labs, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets24.6 M25.9 M78.4 M
Slightly volatile
Short and Long Term Debt Total28.9 M53.3 M25.4 M
Slightly volatile
Total Current Liabilities30 M58.2 M19.9 M
Very volatile
Property Plant And Equipment Net492.1 K518 K29.3 M
Slightly volatile
Current Deferred Revenue2.6 M3.3 M2.4 M
Slightly volatile
Accounts Payable1.8 M1.9 M2.9 M
Very volatile
Cash24.2 M21.6 M39.9 M
Slightly volatile
Non Current Assets Total587.1 K618 K32.8 M
Slightly volatile
Non Currrent Assets Other21.4 K22.5 K650.3 K
Slightly volatile
Cash And Short Term Investments24.2 M21.6 M39.9 M
Slightly volatile
Net Receivables5.9 M5.6 M3.1 M
Slightly volatile
Good Will513.8 K562.8 K631.7 K
Slightly volatile
Common Stock Shares Outstanding35.8 M38.7 M32.5 M
Slightly volatile
Liabilities And Stockholders Equity24.6 M25.9 M78.4 M
Slightly volatile
Non Current Liabilities Total148.2 M141.2 M79 M
Slightly volatile
Inventory3.4 M5.5 M3.7 M
Slightly volatile
Other Current Assets3.2 M3.7 M3.8 M
Slightly volatile
Other Stockholder Equity7.7 M8.1 M125.3 M
Slightly volatile
Total Liabilities116.5 M199.3 M104.6 M
Slightly volatile
Total Current Assets30 M25.3 M46 M
Slightly volatile
Short Term Debt47.3 M45.1 M10.7 M
Slightly volatile
Intangible Assets5.5 M4.6 M4.5 M
Very volatile
Common Stock328.5 K599.3 K372.2 K
Slightly volatile
Long Term Debt5.7 M8.2 M2.9 M
Slightly volatile
Capital Lease Obligations133.7 K194 K64.3 K
Slightly volatile
Property Plant And Equipment Gross625.6 K771 K780.4 K
Slightly volatile
Short and Long Term Debt24.8 M44.9 M4.8 M
Slightly volatile

BioAge Labs, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization153.9 K162 K2.1 M
Pretty Stable
Interest Expense5.7 M7.8 MM
Slightly volatile
Selling General Administrative9.2 M14.5 M8.1 M
Slightly volatile
Selling And Marketing Expenses2.9 M1.7 M3.1 M
Slightly volatile
Other Operating Expenses58.5 M48.4 M48.2 M
Very volatile
Research Development20.3 M33.9 M21.4 M
Slightly volatile
Cost Of Revenue27 M25.7 M14.6 M
Slightly volatile
Total Operating Expenses51.1 M48.4 M44 M
Pretty Stable
Interest Income1.6 M2.4 M671.3 K
Slightly volatile
Reconciled Depreciation160.1 K162 K133.3 K
Slightly volatile

BioAge Labs, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.7 MM4.5 M
Slightly volatile
Begin Period Cash Flow31.1 M27.6 M41.5 M
Pretty Stable
Depreciation153.9 K162 K2.1 M
Pretty Stable
Total Cash From Financing Activities38.5 M34.9 M45.7 M
Slightly volatile
End Period Cash Flow24.6 M25 M40.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio56.1559.1190.6395
Slightly volatile
PTB Ratio33.2131.6321.3442
Slightly volatile
Days Sales Outstanding119137114
Slightly volatile
Book Value Per Share0.570.61.8288
Slightly volatile
Average Payables6.7 M7.6 M8.2 M
Slightly volatile
Stock Based Compensation To Revenue0.380.41.3403
Slightly volatile
Capex To Depreciation0.971.02472.6121
Slightly volatile
PB Ratio33.2131.6321.3442
Slightly volatile
EV To Sales58.5761.6587.1789
Slightly volatile
Inventory Turnover2.184.173.0973
Slightly volatile
Days Of Inventory On Hand86.1690.69162
Slightly volatile
Payables Turnover3.964.1726.8751
Slightly volatile
Sales General And Administrative To Revenue0.760.81.4075
Slightly volatile
Research And Ddevelopement To Revenue0.40.423.1953
Slightly volatile
Capex To Revenue3.844.324.7024
Slightly volatile
Cash Per Share0.120.131.7195
Slightly volatile
Days Payables Outstanding86.0290.55215
Very volatile
Income Quality0.890.58510.8446
Very volatile
Intangibles To Total Assets0.03580.05220.0486
Slightly volatile
Current Ratio0.410.43513.3989
Slightly volatile
Tangible Book Value Per Share0.460.491.6415
Slightly volatile
Receivables Turnover3.272.763.4946
Pretty Stable
Graham Number9.936.028.6451
Slightly volatile
Shareholders Equity Per Share0.570.61.8288
Slightly volatile
Capex Per Share0.660.740.8042
Slightly volatile
Average Receivables684.2 K884.5 K854.3 K
Slightly volatile
Revenue Per Share0.340.320.2624
Slightly volatile
Interest Debt Per Share1.681.031.2768
Slightly volatile
Debt To Assets2.152.04670.4705
Slightly volatile
Price Book Value Ratio33.2131.6321.3442
Slightly volatile
Days Of Payables Outstanding86.0290.55215
Very volatile
Ebt Per Ebit0.851.31930.9804
Slightly volatile
Quick Ratio0.410.43513.3185
Slightly volatile
Net Income Per E B T1.021.110.9681
Pretty Stable
Cash Ratio0.350.37213.0892
Pretty Stable
Days Of Inventory Outstanding86.1690.69162
Slightly volatile
Days Of Sales Outstanding119137114
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.281.00441.1446
Slightly volatile
Price To Book Ratio33.2131.6321.3442
Slightly volatile
Fixed Asset Turnover0.290.270.2175
Slightly volatile
Debt Ratio2.152.04670.4705
Slightly volatile
Price Sales Ratio56.1559.1190.6395
Slightly volatile
Asset Turnover0.20.190.1233
Slightly volatile
Price Fair Value33.2131.6321.3442
Slightly volatile
Operating Cycle313227283
Slightly volatile

BioAge Labs, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap383 M691.3 M544.3 M
Slightly volatile
Enterprise Value388.5 M720.9 M549.2 M
Slightly volatile

BioAge Fundamental Market Drivers

Cash And Short Term Investments21.6 M

About BioAge Labs, Financial Statements

BioAge Labs, stakeholders use historical fundamental indicators, such as BioAge Labs,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although BioAge Labs, investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioAge Labs,'s assets and liabilities are reflected in the revenues and expenses on BioAge Labs,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioAge Labs,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.3 M2.6 M
Cost Of Revenue25.7 M27 M
Stock Based Compensation To Revenue 0.40  0.38 
Sales General And Administrative To Revenue 0.80  0.76 
Research And Ddevelopement To Revenue 0.42  0.40 
Capex To Revenue 4.32  3.84 
Revenue Per Share 0.32  0.34 
Ebit Per Revenue(6.63)(6.96)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether BioAge Labs, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioAge Labs,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioage Labs, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioage Labs, Stock:
Check out the analysis of BioAge Labs, Correlation against competitors.
For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs,. If investors know BioAge will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAge Labs, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.40)
The market value of BioAge Labs, is measured differently than its book value, which is the value of BioAge that is recorded on the company's balance sheet. Investors also form their own opinion of BioAge Labs,'s value that differs from its market value or its book value, called intrinsic value, which is BioAge Labs,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAge Labs,'s market value can be influenced by many factors that don't directly affect BioAge Labs,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAge Labs,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAge Labs, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAge Labs,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.